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Background: Red blood cell (RBC) transfusion is a common event in
the perioperative course of patients undergoing surgery. Transfused blood
can disrupt the balance of coagulation factors and modulate the inflamma-
tory cascade. Since inflammation and coagulation are tightly coupled, we
postulated that RBC transfusion may be associated with the development of
venous thromboembolic phenomena. We queried the American College of
Surgeon’s National Surgical Quality Improvement Program database to
examine the relationship between intraoperative blood transfusion and
development of venous thromboembolism in patients undergoing colorectal
resection for cancer (Table).
Methods: We analyzed the data from 2005 to 2008 for patients
undergoing colorectal resections for cancer based on the primary procedure
Current Procedure Terminology-4 code and operative International Classi-
fication of Diseases-9 diagnosis code. The primary outcomewas 30-day deep
vein thrombosis (DVT) and/or pulmonary embolism (PE). Intraoperative
transfusion of RBCwas categorized as none, 1-2 units, 3-5 units, and 6 units
or more. DVT and/or PE occurrences were analyzed by multivariable
forward stepwise regression (P for entry  .05, for exit  .10) to identify
independent predictors of DVT.
Results: The database contained 21,943 colorectal cancer resections.
The DVT rate was 1.4% (306/21,943), and the PE rate was 0.8% (180/
21,943). Patients were diagnosed with both only 40 times, and the com-
bined DVT or PE rate was 2.0% (446/21,943). After adjusting for age,
gender, race, American Society of Anesthesiologists class, emergency proce-
dure, operative duration, and complexity of the procedure (based on relative
value units), along with six clinical risk factors, intraoperative blood trans-
fusion was a significant risk fact for the development of venous thromboem-
bolism as shown in the following table. Preoperative hematocrit did not
enter the multivariable model as an independent predictor of venous throm-
boembolism, nor did open versus laparoscopic resection. The risk for the
outcome increased with increasing number of units transfused.
Conclusion: In this study of 21,943 patients undergoing colorectal
resection for cancer, blood transfusion is associated with increased risk of
venous thromboembolism. This increased thrombotic risk may be related to
dilution of anticoagulant factors, viscosity changes, or immunologic effects
as well as the formation of microaggregates, which are composed of degen-
erating platelets, granulocyte debris, and fibrin strands; these form rapidly
during blood storage. Malignancy and surgery are known prothrombotic
stimuli. The subset of patients receiving intraoperative RBC transfusions is
even more at risk for venous thromboembolism, emphasizing the need for
sensible use of transfusions and rigorous thromboprophylaxis regimens.
Downregulation of Hypoxia-Inducible Factor-1 Alpha Reduces Ve-
nous Thrombus Resolution
C. E. Evans, J. Humphries, K. Mattock, M. Waltham, A. Wadoodi, P. Saha, B.
Modarai, and A. Smith, King’s College London, London, United Kingdom
Background: Hypoxia-inducible factor-1 (HIF-1)-mediated angio-
genic factors, such as vascular endothelial growth factor (VEGF), are in-
duced within venous thrombus during its resolution, but the primary
stimulus for VEGF production and thrombus resolution is unknown. Our
aim was to determine whether downregulatingHIF-1 in the thrombus and
vein wall reduces angiogenic factor expression, inflammatory cell infiltration,
and thrombus resolution.
Methods: Thrombus was induced in the inferior vena cava (IVC) of 40
mice. The mice were treated with the HIF-1 inhibitor 2-methoxyestradiol
Table.
Intraoperative transfusion
packed red blood cells
30-day venous
thromboembolism rate
M
0 units (n  19,588, 89.3%) 1.8% Re
1-2 units (n  1751, 8.0%) 3.7% 1.
3-5 units (n  466, 2.1%) 4.9% 1.
6 units (n  138, 0.6%) 9.4% 3.189(2ME; intraperitoneal, 150 mg/kg/day) or vehicle control (n  20/
group). HIF-1, VEGF, and placental growth factor (PLGF) expression in
the thrombus and IVC were measured at days 1 and 10 (n  7/group) by
enzyme-linked immunosorbent assay. Thrombus size, neovascularization,
recanalization, and macrophage and neutrophil infiltration were also mea-
sured at day 10 by image analysis (n  6/group).
Results: The levels of HIF-1 (P  .001), VEGF (P  .001), and
PLGF (P .001), and neutrophil (P .005) and macrophage (P .05, Fig
1) infiltration were decreased in the thrombus of mice treated with 2ME
compared with vehicle control. The levels of HIF-1 (P  .005), VEGF (P
 .005), and PLGF (P  .001), and neutrophil (P  .01) and macrophage
(P .005, Fig 2) infiltration were also decreased in the IVC wall surround-
ing the thrombus of 2ME-treated mice compared with controls. Thrombus
weight (P  .001, Fig 3) and size (P  .02, Fig 4) were increased, while
thrombus neovascularization (P .005, Fig 5) and vein recanalization (P
.005, Fig 6) were decreased in 2ME-treated mice compared with controls.
Conclusions: Reducing HIF-1 expression in the thrombus and vein
wall reduces angiogenic growth factor expression, inflammatory cell infiltra-
tion, and thrombus resolution. These data suggest that HIF-1 activity is an
important regulatory mechanism in thrombus resolution.
ariable adjusted
dds ratio 95% confidence interval P value
ce
1.047 1.854 .023
1.187 2.985 .007ultiv
o
feren
393
8831.704 5.966 .000
251
